Now that Lilly (NYSE: LLY) has decided to enter the insulin pump market, one must wonder how long it will take Novo Nordisk (NYSE: NVO) and Sanofi (NYSE: SNY) to follow. We should note that Novo was an investor in Asante which failed and was bought by Bigfoot after they declared bankruptcy. Yes, if there is one thing we count on in this wacky world it’s there is no such thing as an original idea. That far too often money is thrown at something not because it’s better rather because the competition is doing it, so we should . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.